Experienced in Teratocarcinosarcoma

Dr. Darcy V. Spicer

Oncology
USC Care Medical Group Inc
1520 San Pablo St, 
Los Angeles, CA 
Offers Telehealth
Experienced in Teratocarcinosarcoma
USC Care Medical Group Inc
1520 San Pablo St, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Darcy Spicer is an Oncologist in Los Angeles, California. Dr. Spicer is rated as an Experienced provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma.

His clinical research consists of co-authoring 30 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Los Angeles General Medical Center
Keck Hospital Of USC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

USC CARE MEDICAL GROUP INC
1520 San Pablo St, Los Angeles, CA 90033
Other Locations
USC CARE MEDICAL GROUP INC
1500 San Pablo St, Los Angeles, CA 90033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen
Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen
Enrollment Status: Terminated
Publish Date: October 05, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: capecitabine, cyclophosphamide, lapatinib ditosylate, trastuzumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Control Pilot Trial of Xuanfei Baidu Granules (XFBD), a Traditional Chinese Medicine (TCM), in Persons With COVID-19
A Randomized, Double-Blind, Placebo-Control Pilot Trial of Xuanfei Baidu Granules (XFBD), a Traditional Chinese Medicine (TCM), in Persons With COVID-19
Enrollment Status: Terminated
Publish Date: June 27, 2022
Intervention Type: Drug, Other
Study Drug: Xuanfei Baidu
Study Phase: Phase 2
A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): A Financial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials
A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): A Financial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials
Enrollment Status: Terminated
Publish Date: November 16, 2021
Intervention Type: Behavioral, Other
Study Phase: Not Applicable
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

30 Total Publications

MammaTrace - a cell-free DNA methylation plasma only assay for minimal residual disease detection in breast cancer patients.
MammaTrace - a cell-free DNA methylation plasma only assay for minimal residual disease detection in breast cancer patients.
Journal: medRxiv : the preprint server for health sciences
Published: June 06, 2025
Similar Doctors
Distinguished in Teratocarcinosarcoma
Dr. Chaitali S. Nangia
Hematology Oncology | Hematology | Oncology
Distinguished in Teratocarcinosarcoma
Dr. Chaitali S. Nangia
Hematology Oncology | Hematology | Oncology

Hoag Clinic

1 Hoag Dr, 
Newport Beach, CA 
 (34.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chaitali Nangia is a Hematologist Oncology specialist and a Hematologist in Newport Beach, California. Dr. Nangia is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Breast Cancer, Olfactory Neuroblastoma, Teratocarcinosarcoma, and Paget Disease of the Breast.

Advanced in Teratocarcinosarcoma
Dr. Rupali K. Nabar
Oncology | Hematology
Advanced in Teratocarcinosarcoma
Dr. Rupali K. Nabar
Oncology | Hematology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (26.1 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rupali Nabar is an Oncologist and a Hematologist in Orange, California. Dr. Nabar is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Laryngeal Cancer, Squamous Cell Skin Carcinoma, Bone Tumor, and Teratocarcinosarcoma.

Advanced in Teratocarcinosarcoma
Dr. Jennifer B. Valerin
Oncology | Hematology
Advanced in Teratocarcinosarcoma
Dr. Jennifer B. Valerin
Oncology | Hematology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (26.1 miles away)
714-456-7002
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jennifer Valerin is an Oncologist and a Hematologist in Orange, California. Dr. Valerin has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Melanoma, and Undifferentiated Pleomorphic Sarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Spicer's expertise for a condition
ConditionClose
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile